Job title: Chief Scientific Officer
Dr. Evans obtained his BSc and PhD from Imperial College, London. Over the last 3 decades he has built scientific research teams focused on target validation, drug discovery and high throughput screening of small molecule and siRNA libraries to identify lead candidates for development in Oncology and other indications. David has more than 15 years’ experience in the RNAi field – building genome scale screening capabilities for target identification in Oncology and other indications at TGEN and Dharmacon prior to cofounding Sirnaomics to focus on developing siRNA as a therapeutic. David previously worked at the Frederick National Lab for Cancer Research and in the Boston area with Millennium Pharmaceuticals and Serono Pharmaceuticals.
Delivering Multiple siRNAs for the Treatment of Oncology & Fibrosis 1:50 pm
Our proprietary polypeptide nanoparticle (PNP) platform can carry multiple siRNA sequences to viable targets Silencing more than one target using PNP can have profound improvements on the efficacy of RNAi therapeutics Sirnaomics is currently driving multiple therapeutic programs through pre-clinical and clinical developmentRead more